Please check your internet connection and try again.
# Mydol® (Acetaminophen/Caffeine/Carisoprodol)
## Overview
Mydol® is a combination product containing acetaminophen, caffeine, and carisoprodol. Acetaminophen is an analgesic and antipyretic. Caffeine is a stimulant that may enhance acetaminophen's analgesic effect. Carisoprodol is a centrally acting skeletal muscle relaxant.
## Primary Indications
* Short-term management of acute pain associated with muscle spasm.
## Adult Dosing
* **Typical Dose:** 1-2 tablets (acetaminophen 325 mg/caffeine 40 mg/carisoprodol 200 mg or acetaminophen 650 mg/caffeine 80 mg/carisoprodol 400 mg depending on tablet strength) orally every 6 hours as needed.
* **Maximum Dose:** Do not exceed 4 tablets in 24 hours. Higher doses do not increase efficacy and increase the risk of serious adverse events.
## Pediatric Dosing
* Safety and efficacy in pediatric patients have not been established.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Carisoprodol is metabolized by the liver.
* **Renal Impairment:** Use with caution. Carisoprodol is excreted renally. Patients with severe renal impairment may have increased carisoprodol and metabolite levels.
* **Elderly:** Use with caution. Elderly patients may be more susceptible to the CNS effects of carisoprodol.
## Contraindications
* **Hypersensitivity:** Known hypersensitivity to carisoprodol, meprobamate, or any component of the formulation.
* **Porphyria:** Carisoprodol is metabolized to meprobamate, which may precipitate or exacerbate acute intermittent porphyria.
* **Respiratory Depression:** Patients with acute intermittent porphyria or a history of porphyria.
## Adverse Effects
* **Common:** Drowsiness, dizziness, headache, nausea, vomiting, gastrointestinal upset.
* **Serious:**
* **Carisoprodol-related:** Sedation, dizziness, ataxia, respiratory depression (especially with overdose or concomitant CNS depressants), dependence, withdrawal symptoms upon abrupt discontinuation.
* **Acetaminophen-related:** Hepatotoxicity (especially with overdose or chronic alcohol use).
* **Allergic reactions:** Rash, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis.
## Key Drug Interactions
* **CNS Depressants:** Increased sedation and respiratory depression when used with alcohol, benzodiazepines, opioids, antihistamines, antipsychotics, and other CNS depressants.
* **CYP2C19 Inhibitors:** Carisoprodol is metabolized by CYP2C19. Inhibitors (e.g., fluconazole, fluvoxamine) may increase carisoprodol levels.
* **CYP2C19 Inducers:** Inducers (e.g., rifampin, carbamazepine) may decrease carisoprodol levels.
## Monitoring
* Assess pain relief and muscle spasm resolution.
* Monitor for signs of sedation, dizziness, and cognitive impairment.
* Monitor for signs of dependence or withdrawal, especially with prolonged use or abrupt discontinuation.
* Monitor liver function tests if risk factors for hepatotoxicity are present.
## Clinical Pearls
* Mydol® is intended for short-term use only due to the risk of dependence and withdrawal associated with carisoprodol.
* Patients should be advised to avoid alcohol and other CNS depressants while taking this medication.
* Warn patients about the potential for drowsiness and impairment of motor skills.
* Abrupt discontinuation of carisoprodol can lead to withdrawal symptoms, including anxiety, insomnia, tremors, and nausea.
***
**Disclaimer:** This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information or a drug information database for the most current and complete details. Always verify current prescribing information before making clinical decisions.
